CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, announced today that it granted restricted stock units (RSUs) totaling 44,000 shares to 14 new employees on September 12, 2024, as an inducement for joining the company. These RSUs were issued under the 2019 Inducement Equity Incentive Plan, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The RSUs are distributed as follows:
- 9,000 shares: Vested over four years, with 25% vesting on the first anniversary and the remainder in three equal annual installments.
- 14,000 shares: Vested over four years, with 25% vesting on the first anniversary and the remainder in quarterly installments over three years.
- 18,000 shares: Vested over three years, with 33.33% vesting on the first anniversary and the remainder in quarterly installments over two years.
- 2,000 shares: Vested over two years, with 50% vesting on each of the first two anniversaries.
- 1,000 shares: Vested over two years, with 50% vesting on the first anniversary and the remainder in quarterly installments over the following year.
This announcement complies with Nasdaq Listing Rule 5635(c)(4).
About CareDx:
Headquartered in Brisbane, California, CareDx is a leading precision medicine company specializing in high-value solutions for transplant patients. The company provides comprehensive testing services, products, and digital solutions throughout the pre- and post-transplant journey, and is a prominent provider of genomics-based information for transplant care.
